Cargando…
Genome-independent hypoxic repression of estrogen receptor alpha in breast cancer cells
BACKGROUND: About 75–80% of breast tumors express the estrogen receptor alpha (ER-α) and are treated with endocrine-target therapeutics, making this the premier therapeutic modality in the breast cancer clinic. However, acquired resistance is common and about 20% of resistant tumors loose ER-α expre...
Autores principales: | Padró, Mercè, Louie, Raymond J., Lananna, Brian V., Krieg, Adam J., Timmerman, Luika A., Chan, Denise A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358051/ https://www.ncbi.nlm.nih.gov/pubmed/28320353 http://dx.doi.org/10.1186/s12885-017-3140-9 |
Ejemplares similares
-
xCT inhibition sensitizes tumors to γ-radiation via glutathione reduction
por: Cobler, Lara, et al.
Publicado: (2018) -
Transcriptional repression of estrogen receptor alpha by YAP reveals the Hippo pathway as therapeutic target for ER(+) breast cancer
por: Ma, Shenghong, et al.
Publicado: (2022) -
TWIST Represses Estrogen Receptor-alpha Expression by Recruiting the NuRD Protein Complex in Breast Cancer Cells
por: Fu, Junjiang, et al.
Publicado: (2012) -
Estrogen-repressed genes – key mediators of estrogen action?
por: Zubairy, Simeen, et al.
Publicado: (2005) -
The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer
por: Allred, D Craig, et al.
Publicado: (2004)